How similar is your antibody to clinical-stage therapeutics?
For a full description of the profiler, or if you use this software, please refer to: Raybould MIJ, et al. Five Computational Developability Guidelines for Therapeutic Antibody Profiling. PNAS. (2019)
Please cite our paper "Five Computational Developability Guidelines for Therapeutic Antibody Profiling" if making use of these datasets.
NB: As of 27 June 2022, the TAP protocol was updated to use Fv models generated by ABodyBuilder-ML, our new machine-learning based version of ABodyBuilder that uses ABlooper for CDR modelling. TAP scores and therapeutic thresholds have changed accordingly. Please avoid interpreting the results from previous TAP runs against these new thresholds; instead resubmit your sequences to TAP to ensure the modelling methodology is consistent
|Property||Amber Region (27th June 2022)||Red Region (27th June 2022)|
|Total CDR Length (L)||38 ≤ L ≤ 43||L < 38|
|55 ≤ L ≤ 63||L > 63|
|Patches of Surface Hydrophobicity (PSH)||77.58 ≤ PSH ≤ 94.92||PSH < 77.58|
|151.07 ≤ PSH ≤ 182.49||PSH > 182.49|
|Patches of Positive Charge (PPC)||1.30 ≤ PPC ≤ 3.71||PPC > 3.71|
|Patches of Negative Charge (PNC)||1.97 ≤ PNC ≤ 3.65||PNC > 3.65|
|Structural Fv Charge Symmetry Parameter (SFvCSP)||-19.6 ≤ SFvCSP ≤ -4.95||SFvCSP < -19.6|
Please visit Thera-SAbDab to access our latest CST sequence data.